References
Ahmad, F. B., L. M. Rossen, and P. Sutton. 2020. Provisional drug overdose death counts (NCHS Vital Statistics Rapid Release). https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#citation (accessed January 18, 2021).
Andrilla, C. H. A., T. E. Moore, D. G. Patterson, and E. H. Larson. 2019. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. Journal of Rural Health 35(1):108–112. doi: 10.1111/jrh.12307.
Ashford, R. D., B. Curtis, and A. M. Brown. 2018. Peer-delivered harm reduction and recovery support services: Initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduction Journal 15(1):52. doi: 10.1186/s12954-018-0258-2.
Bach, P., and D. Hartung. 2019. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice 14(1):30. doi: 10.1186/s13722-019-0158-0.
Becan, J. E., J. P. Bartkowski, D. K. Knight, T. R. A. Wiley, R. DiClemente, L. Ducharme, W. N. Welsh, D. Bowser, K. McCollister, M. Hiller, A. C. Spaulding, P. M. Flynn, A. Swartzendruber, M. F. Dickson, J. H. Fisher, and G. A. Aarons. 2018. A model for rigorously applying the Exploration, Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement of a large scale collaborative multi-site study. Health & Justice 6(1):9. doi: 10.1186/s40352-018-0068-3.
Bray, J. W., F. K. Del Boca, B. G. McRee, S. W. Hayashi, and T. F. Babor. 2017. Screening, Brief Intervention and Referral to Treatment (SBIRT): Rationale, program overview and cross-site evaluation. Addiction 112(Suppl 2):3–11.
Brown, M., M. Rowe, A. Cunningham, and A. N. Ponce. 2018. Evaluation of a comprehensive SAMHSA service program for individuals experiencing chronic homelessness. The Journal of Behavioral Health Services & Research 45(4):605–613. doi: 10.1007/s11414-018-9589-8.
CDC (Centers for Disease Control and Prevention). 2018. New data show growing complexity of drug overdose deaths in America. https://www.cdc.gov/media/releases/2018/p1221-complexity-drug-overdose.html (accessed January 12, 2021).
CDC. 2019. Other drugs. https://www.cdc.gov/drugoverdose/data/otherdrugs.html (accessed March 2, 2020).
CDC. 2020a. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID19 pandemic (Health Alert Network). https://emergency.cdc.gov/han/2020/han00438.asp (accessed February 1, 2021).
CDC. 2020b. Synthetic opioid overdose data. https://www.cdc.gov/drugoverdose/data/fentanyl.html (accessed March 2, 2020).
Czeisler, M. É., R. I. Lane, E. Petrosky, J. F. Wiley, A. Christensen, R. Njai, M. D. Weaver, R. Robbin, E. R. Facer-Childs, L. K. Barger, C. A. Czeisler, M. E. Howard, and S. M. W. Rajaratnam. 2020. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24–30, 2020. Morbidity and Mortality Weekly Report 69(32):1049–1057. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm (accessed January 12, 2021).
Dasgupta, N., L. Beletsky, and D. Ciccarone. 2018. Opioid crisis: No easy fix to its social and economic determinants. American Journal of Public Health 108(2):182–186. doi: 10.2105/AJPH.2017.304187.
Davis, C. S., S. Ruiz, P. Glynn, G. Picariello, and A. Y. Walley. 2014. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. American Journal of Public Health 104(8):e7–e9. doi: 10.2105/AJPH.2014.302062.
Englander, H., J. Gregg, J. Gullickson, O. Cochran-Dumas, C. Colasurdo, J. Alla, D. Collins, and C. Nicolaidis. 2020. Recommendations for integrating peer mentors in hospital-based addiction care. Substance Abuse 41(4):419–424. doi: 10.1080/08897077.2019.1635968.
GAO (Government Accountability Office). 2018. Medicaid demonstrations: Evaluations yielded limited results, underscoring need for changes to federal policies and procedures, GAO-18-220. Washington, DC: GAO.
Glasgow, R. E., H. G. McKay, J. D. Piette, and K. D. Reynolds. 2001. The RE-AIM framework for evaluating interventions: What can it tell us about approaches to chronic illness management? Patient Education and Counseling 44(2):119–127. doi: 10.1016/s0738-3991(00)00186-5.
Gostin, L. O., J. G. Hodge, Jr., and S. A. Noe. 2017. Reframing the opioid epidemic as a national emergency. Journal of the American Medical Association 318(16):1539–1540. doi: 10.1001/jama.2017.13358.
Guy, G. P., Jr., T. M. Haegerich, M. E. Evans, J. L. Losby, R. Young, and C. M. Jones. 2019. Vital Signs: Pharmacy-based naloxone dispensing—United States, 2012–2018. Morbidity and Mortality Weekly Report 68(31):679–686. https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6831e1-H.pdf (accessed January 12, 2021).
HHS (Department of Health and Human Services). 2021 (January 7). Renewal of determination that a public health emergency exists. https://www.phe.gov/emergency/news/healthactions/phe/Pages/opioids-7Jan2021.aspx (accessed February 8, 2021).
HHS OIG (Office of Inspector General). 2020. Geographic disparities affect access to buprenorphine services for opioid use disorder. https://oig.hhs.gov/oei/reports/oei-12-17-00240.asp (accessed February 12, 2021).
Jacob, R. T., R. D. Goddard, and E. S. Kim. 2014. Assessing the use of aggregate data in the evaluation of school-based interventions: Implications for evaluation research and state policy regarding public-use data. Educational Evaluation and Policy Analysis 36(1):44–66. doi: 10.3102/0162373713485814.
Krieger, M. S., W. C. Goedel, J. A. Buxton, M. Lysyshyn, E. Bernstein, S. G. Sherman, J. D. Rich, S. E. Hadland, T. C. Green, and B. D. Marshall. 2018a. Use of rapid fentanyl test strips among young adults who use drugs. International Journal of Drug Policy 61:52–58. doi: 10.1016/j.drugpo.2018.09.009.
Krieger, M. S., J. L. Yedinak, J. A. Buxton, M. Lysyshyn, E. Bernstein, J. D. Rich, T. C. Green, S. E. Hadland, and B. D. Marshall. 2018b. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduction Journal 15(1):7. doi: 10.1186/s12954-018-0213-2.
Lago, L. 2013. Statistical methods for analysis of aggregate health performance data. Presented to the COAG Reform Council at the Centre for Health Service Development, Australia Health Service Research Institute, Wollongong, Australia. https://ro.uow.edu.au/cgi/viewcontent.cgi?referer=https://www.google.com/&httpsredir=1&article=1261&context=ahsri (accessed February 12, 2021).
McHugo, G. J., N. Kammerer, E. W. Jackson, L. S. Markoff, M. Gatz, M. J. Larson, R. Mazelis, and K. Hennigan. 2005. Women, Co-occurring Disorders, and Violence Study: Evaluation design and study population. Journal of Substance Abuse Treatment 28(2):91–107. doi: 10.1016/j.jsat.2004.08.009.
NASEM (National Academies of Sciences, Engineering, and Medicine). 2017. Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Academies Press. https://doi.org/10.17226/24781.
NASEM. 2019. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press. https://doi.org/10.17226/25310.
NASEM. 2020a. Opportunities to improve opioid use disorder and infectious disease services: Integrating responses to a dual epidemic. Washington, DC: The National Academies Press. https://doi.org/10.17226/25626.
NASEM. 2020b. Measuring success in substance use grant programs: Outcomes and metrics for improvement. Washington, DC: The National Academies Press. https://doi.org/10.17226/25745.
Naumann, R. B., C. P. Durrance, S. I. Ranapurwala, A. E. Austin, S. Proescholdbell, R. Childs, S. W. Marshall, S. Kansagra, and M. E. Shanahan. 2019. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug and Alcohol Dependence 204:107536. doi: 10.1016/j.drugalcdep.2019.06.038.
NIDA (National Institute on Drug Abuse). 2020. Overdose death rates. https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates (accessed December 28, 2020).
Oquendo, M. A., and N. D. Volkow. 2018. Suicide: A silent contributor to opioid-overdose deaths. The New England Journal of Medicine 378(17):1567–1569. doi: 10.1056/NEJMp1801417.
Peiper, N. C., S. D. Clarke, L. B. Vincent, D. Ciccarone, A. H. Kral, and J. E. Zibbell. 2019. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the southeastern United States. International Journal of Drug Policy 63:122–128. https://doi.org/10.1016/j.drugpo.2018.08.007.
Ryan, S. A., and C. B. Thompson. 2002. The use of aggregate data for measuring practice improvement. Seminars for Nurse Managers 10(2):90–94.
Saloner, B., and J. C. Maclean. 2020. Specialty substance use disorder treatment admissions steadily increased in the four years after Medicaid expansion. Health Affairs 39(3):453–461. doi: 10.1377/hlthaff.2019.01428.
SAMHSA (Substance Abuse and Mental Health Services Administration). 2013. Government Performance and Results Act (GPRA) client outcome measures for discretionary programs: Question-by-question instruction guide. https://www.samhsa.gov/sites/default/files/GPRA/SAIS_GPRA_Services_Tool_QxQ_final.pdf (accessed February 23, 2021).
SAMHSA. 2016. Facing addiction in America: The Surgeon General’s report on alcohol, drugs, and health. https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf (accessed December 30, 2020).
SAMHSA. 2017a. Comprehensive Addiction and Recovery Act: Building communities of recovery: (Initial announcement) Funding Opportunity Announcement TI-17-015. https://www.samhsa.gov/grants/grant-announcements/ti-19-003 (accessed March 13, 2020).
SAMHSA. 2017b. Comprehensive Addiction and Recovery Act: State pilot grant program for treatment for pregnant and postpartum women: (Initial Announcement) Funding Opportunity Announcement TI-17-016. https://www.samhsa.gov/grants/grant-announcements/ti-20-010 (accessed March 13, 2020).
SAMHSA. 2017c. First responders—Comprehensive Addiction and Recovery Act: (Initial Announcement) Funding Opportunity Announcement SP-17-005. https://www.samhsa.gov/grants/grant-announcements/ti-19-004 (accessed March 3, 2020).
SAMHSA. 2017d. Improving access to overdose treatment: (Initial Announcement) Funding Opportunity Announcement SP-17-006. https://www.samhsa.gov/grants/grant-announcements/sp-18-006 (accessed March 13, 2020).
SAMHSA. 2017e. SP-17-005 individual grant awards 2017. https://www.samhsa.gov/grants/awards/2017/SP-17-005 (accessed December 30, 2020).
SAMHSA. 2017f. SP-17-006 individual grant awards 2017. https://www.samhsa.gov/grants/awards/2017/SP-17-006 (accessed December 30, 2020).
SAMHSA. 2017g. TI-17-015 individual grant awards 2017. https://www.samhsa.gov/grants/awards/2017/TI-17-015 (accessed December 30, 2020).
SAMHSA. 2017h. TI-17-016 individual grant awards 2017. https://www.samhsa.gov/grants/awards/2017/TI-17-016 (accessed December 30, 2020).
SAMHSA. 2018a. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf (accessed January 12, 2021).
SAMHSA, 2018b. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA.
SAMHSA, 2018c. Minority AIDS Initiative (MAI) cross-site evaluation: Final report. Rockville, MD: SAMHSA.
SAMHSA. 2018d. SP-17-005 individual grant awards 2018. https://www.samhsa.gov/grants/awards/2018/SP-17-005 (accessed December 30 2020).
SAMHSA. 2018e. SP-18-006 individual grant awards 2018. https://www.samhsa.gov/grants/awards/2018/SP-18-006 (accessed December 30, 2020).
SAMHSA. 2018f. TI-17-015 individual grant awards 2018. https://www.samhsa.gov/grants/awards/2018/TI-17-015 (accessed December 30, 2020).
SAMHSA. 2018g. TI-17-016 individual grant awards 2018. https://www.samhsa.gov/grants/awards/2018/TI-17-016 (accessed December 30, 2020).
SAMHSA. 2019a. A guide to SAMHSA’s strategic prevention framework. Rockville, MD: SAMHSA.
SAMHSA. 2019b. TI-19-003 individual grant awards 2019. https://www.samhsa.gov/grants/awards/2019/TI-19-003 (accessed February 12, 2021).
SAMHSA. 2020a. Building Communities of Recovery: (Modified Announcement) Funding Opportunity Announcement TI-21-004. https://www.samhsa.gov/grants/grant-announcements/TI-21-004 (accessed February 12, 2021).
SAMHSA. 2020b. State Pilot Grant Program for Treatment for Pregnant and Postpartum Women: (Modified Announcement) Funding Opportunity Announcement TI-21-002. https://www.samhsa.gov/grants/grant-announcements/ti-21-002 (accessed February 12, 2021).
Scharf, D. M., N. K. Eberhart, N. S. Hackbarth, M. Horvitz-Lennon, R. Beckman, B. Han, S. L. Lovejoy, H. A. Pincus, and M. A. Burnam. 2014. Evaluation of the SAMHSA Primary and Behavioral Health Care Integration (PBHCI) grant program: Final report. RAND Health Quarterly 4(3):6.
Schumann, H., T. Erickson, T. M. Thompson, J. L. Zautcke, and J. S. Denton. 2008. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clinical Toxicology (Philadelphia, PA.) 46(6):501–506. doi: 10.1080/15563650701877374.
Seth, P., L. Scholl, R. A. Rudd, and S. Bacon. 2018. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. Morbidity and Mortality Weekly Report 67(12):349–358. https://www.cdc.gov/mmwr/volumes/67/wr/mm6712a1.htm (accessed January 12, 2021).
Slavova, S., P. Rock, H. M. Bush, D. Quesinberry, and S. L. Walsh. 2020. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug and Alcohol Dependence 214:108176. doi: 10.1016/j. drugalcdep.2020.108176.
Somerville, N. J., J. O’Donnell, R. M. Gladden, J. E. Zibbell, T. C. Green, M. Younkin, S. Ruiz, H. Babakhanlou-Chase, M. Chan, B. P. Callis, J. Kuramoto-Crawford, H. M. Nields, and A. Y. Walley. 2017. Characteristics of fentanyl overdose—Massachusetts, 2014–2016. Morbidity and Mortality Weekly Report 66(14):382–386. doi: 10.15585/mmwr.mm6614a2.
Stack, E., G. Leichtling, J. E. Larsen, M. Gray, J. Pope, J. M. Leahy, L. Gelberg, A. Seaman, and P. T. Korthuis. 2020. The impacts of COVID-19 on mental health, substance use, and overdose concerns of people who use drugs in rural communities. Journal of Addiction Medicine, online ahead of print. doi: 10.1097/ADM.0000000000000770.
Steadman, H. J., M. W. Deane, J. P. Morrissey, M. L. Westcott, S. Salasin, and S. Shapiro. 1999. A SAMHSA research initiative assessing the effectiveness of jail diversion programs for mentally ill persons. Psychiatric Services 50(12):1620–1623. doi: 10.1176/ps.50.12.1620.
Torralva, R., and A. Janowsky. 2019. Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. Journal of Pharmacology and Experimental Therapeutics 371(2):453–475. doi: 10.1124/jpet.119.258566.
Volkow, N. D., and C. Blanco. 2020. The changing opioid crisis: Development, challenges and opportunities. Molecular Psychiatry, online ahead of print. doi: 10.1038/s41380-020-0661-4.
Wakeman, S. E., Y. Chang, S. Regan, L. Yu, J. Flood, J. Metlay, and N. Rigotti. 2019. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. Journal of Addiction Medicine 13(4):253–257. doi: 10.1097/ADM.0000000000000486.
Williams, A. R., E. V. Nunes, A. Bisaga, F. R. Levin, and M. Olfson. 2019. Development of a Cascade of Care for responding to the opioid epidemic. American Journal of Drug and Alcohol Abuse 45(1):1–10. doi: 10.1080/00952990.2018.1546862.